Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 15/20 | 0.41 |
| ▸ | LCK | P06239 | 13/20 | 0.41 |
| ▸ | EGFR | P00533 | 12/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893639 | 0.89 | JAK3 (0.39) | JAK3LCKEGFRBTKJAK2 | |
| SCHEMBL10169338 | 0.82 | SYK (0.52) | EGFRBTK | |
| SCHEMBL10169441 | 0.80 | STAT6 (0.51) | JAK3LCKEGFRBTKPARP1 | |
| SCHEMBL10169403 | 0.79 | SYK (0.44) | JAK2JAK1 | |
| SCHEMBL10169425 | 0.78 | FLT3 (0.55) | JAK3BTKJAK2JAK1 | |
| SCHEMBL10169433 | 0.77 | MEN1 (0.47) | JAK3BTKJAK2JAK1 | |
| SCHEMBL10169371 | 0.77 | STAT6 (0.55) | — | |
| SCHEMBL10169331 | 0.76 | BTK (0.57) | JAK3LCKEGFRBTKJAK2 | |
| SCHEMBL10169520 | 0.76 | PARP1 (0.48) | JAK3LCKEGFRBTKPARP1 | |
| SCHEMBL894595 | 0.74 | BTK (0.37) | JAK3LCKEGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | JAK3 418/4885LCK 31/4885EGFR 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.